Resurge Therapeutics, a clinical-stage urology company, today announced positive clinical results from two studies evaluating ...
Today, the American Urological Association (AUA) released the 2026 Management of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign Prostatic Hyperplasia (BPH) Guideline, providing updated, ...
GlobalData on MSN
Butterfly Medical raises $21m in funds for BPH device development
The company has completed its pivotal clinical trial for the Butterfly prostatic retraction device.
PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of lower urinary tract symptoms (LUTS) attributed to ...
Benign Prostatic Hyperplasia Surgical Treatment Market OverviewThe global benign prostatic hyperplasia surgical treatment ...
Medical Device Network on MSN
Rivermark pockets $20M in Series D for late-stage prostate device trial
The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for ...
Contemporary diagnosis of very low risk prostate cancer in a multi-centered hospital system. Use of the Prostatype P-score to predict adverse pathology (AP) at radical prostatectomy (RP). This is an ...
Your urologist will use several tests to determine how severe your BPH is and whether it affects your bladder health. They may recommend watchful waiting if your BPH is mild. Watchful waiting means ...
An enlarged prostate—also known as benign prostatic hyperplasia (BPH)—is a natural sign of aging that affects half of all men over the age of 40. The good news is this condition does not increase your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results